Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

394 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical effectiveness and cost effectiveness of tailoring chronic hepatitis C treatment with peginterferon alpha-2b plus ribavirin to HCV genotype and early viral response: a decision analysis based on German guidelines.
Siebert U, Sroczynski G, Aidelsburger P, Rossol S, Wasem J, Manns MP, McHutchison JG, Wong JB. Siebert U, et al. Among authors: mchutchison jg. Pharmacoeconomics. 2009;27(4):341-54. doi: 10.2165/00019053-200927040-00006. Pharmacoeconomics. 2009. PMID: 19485429 Clinical Trial.
Economic and clinical effects of evaluating rapid viral response to peginterferon alfa-2b plus ribavirin for the initial treatment of chronic hepatitis C.
Wong JB, Davis GL, McHutchison JG, Manns MP, Albrecht JK; International Hepatitis Interventional Therapy Group. Wong JB, et al. Among authors: mchutchison jg. Am J Gastroenterol. 2003 Nov;98(11):2354-62. doi: 10.1111/j.1572-0241.2003.t01-1-08735.x. Am J Gastroenterol. 2003. PMID: 14638334 Clinical Trial.
Cost effectiveness of peginterferon alpha-2b plus ribavirin versus interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C.
Siebert U, Sroczynski G, Rossol S, Wasem J, Ravens-Sieberer U, Kurth BM, Manns MP, McHutchison JG, Wong JB; German Hepatitis C Model (GEHMO) Group; International Hepatitis Interventional Therapy (IHIT) Group. Siebert U, et al. Among authors: mchutchison jg. Gut. 2003 Mar;52(3):425-32. doi: 10.1136/gut.52.3.425. Gut. 2003. PMID: 12584228 Free PMC article. Clinical Trial.
Cost-effectiveness of truncated therapy for hepatitis C based on rapid virologic response.
Gellad ZF, Muir AJ, McHutchison JG, Sievert W, Sharara AI, Brown KA, Flisiak R, Jacobson IM, Kershenobich D, Manns MP, Schulman KA, Reed SD. Gellad ZF, et al. Among authors: mchutchison jg. Value Health. 2012 Sep-Oct;15(6):876-86. doi: 10.1016/j.jval.2012.06.010. Epub 2012 Aug 9. Value Health. 2012. PMID: 22999138 Free article.
Antiviral treatment initiation costs in chronic hepatitis C.
Siebert U, Wasem J, Rossol S, Sroczynski G, Aidelsburger P, Ravens-Sieberer U, Kurth BM, Manns MP, McHutchison JG, Wong JB. Siebert U, et al. Among authors: mchutchison jg. Gut. 2005 Jan;54(1):172-3. Gut. 2005. PMID: 15591531 Free PMC article. No abstract available.
394 results